Korro Bio vs Seres Therapeutics
KRRO and MCRB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KRRO and MCRB compare
Korro Bio is the larger company, worth 13 times as much as Seres Therapeutics ($187M against $14.0M).
Seres Therapeutics keeps more of each dollar of sales as profit, with a net margin of −1193% compared with −4477% at Korro Bio.
Seres Therapeutics scores higher on the StockData Score (6 against 5 for Korro Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KRRO | MCRB |
|---|---|---|
| Size and price | ||
| Market cap | $187M | $14.0M |
| Share price | $12.71 | $1.41 |
| Change, 1 year | 95.5% | −91.6% |
| Change, 5 years | −95.5% | −99.2% |
| Beta (5Y) | 2.43 | 0.28 |
| Employees | 58 | 66 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 78.6× | 7.4× (better) |
| P/B | – | 0.4× |
| FCF yield | −36.5% (better) | −366% |
| Growth | ||
| Revenue growth (TTM) | −62.1% | – |
| Revenue growth, 5Y average | −29.6% (better) | −52.7% |
| Net income growth (TTM) | – | −126% |
| EPS growth (TTM) | – | −121% |
| Profitability | ||
| Operating margin | −4625% | −4463% (better) |
| Net margin | −4477% | −1193% (better) |
| FCF margin | −2866% | −2724% (better) |
| Return on equity | – | −66.6% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 9.55 (better) | 2.11 |
| Altman Z-score | −3.17 (better) | −15.93 |
| Piotroski F-score | 2 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 102% | 22.9% |
| Held by insiders | 27.4% | 2.3% |
| Insider net buying, 12 months | $15.0M (better) | −$10.0K |
| Short interest, % of float | 16.4% | 3.5% |
Go deeper
- KRRO stock overview
- KRRO income statement
- KRRO valuation and score
- MCRB stock overview
- MCRB income statement
- MCRB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.